K858 (Racemic)

• UNSPSC Description:

  K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.

• Target Antigen:

  Apoptosis; Kinesin

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/K858.html

• Purity:

  99.93

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(NC1=NN(C(C)=O)C(C2=CC=CC=C2)(C)S1)=O

• Molecular Weight:

  277.349

• References & Citations:

  [1]Nakai R, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009 May 1;69(9):3901-9.|[2]De Iuliis F, et al. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs. 2016 Aug;34(4):399-406.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  72926-24-0